Study identifies a novel molecule that prevents the symptoms associated with allergen-induced asthma.
A new study carried out by researchers at Sanford-Burnham Medical Research Institute (Sanford-Burnham), the Max Planck Institute for Colloids and Interfaces (Germany), the Free University of Berlin (Germany), UC San Diego, and Shinshu University (Japan) has identified a novel molecule that prevents T-cells from orchestrating asthma brought on by allergens.
The findings, published on May 12 in Proceedings of the National Academy of Sciences (PNAS), show promise for a new potent therapeutic agent to treat asthma, a chronic disease affecting more than 25 million Americans.
“We have identified a synthetic molecule, a sulfate monosaccharide, that inhibits the signal that recruits T-cells to the lungs to start an asthma attack,” said Minoru Fukuda, Ph.D., adjunct professor in the Tumor Microenvironment and Metastasis Program at Sanford-Burnham. “The molecule substantially lessened asthma symptoms such as inflammation, mucus production, and airway constriction.”
The study, performed in mouse models for asthma research, showed that the synthetic sulfate monosaccharide blocks the interaction between chemokine CCL20—a T-cell signaling protein—and heparin sulfate, a molecule that protects and immobilizes CCL20 on epithelial cells in the lung. Blocking this interaction stalled the recruitment of the T-cells that trigger inflammation. The favorable results were achieved when the novel molecule was administered intravenously as well as by inhalation.
Although billions of dollars are spent every year on asthma medication, asthma still accounts for one quarter of all emergency room visits in the U.S. each year (~1.75 million ER visits). And, asthma is on the rise. Since 1980, asthma death rates overall have increased more than 50 percent among all genders, age groups, and ethnic groups. The death rate for children under 19 years old has increased by nearly 80 percent since 1980.
“There is currently no cure for asthma, and asthma control remains elusive for many patients, so there is still a need for research to find new therapies,” says Mike Tringale, senior vice president at the Asthma and Allergy Foundation of America (AAFA), a national asthma patient organization that has declared May National Asthma Awareness Month.
“Pulmonary inhalation of this new molecule may help reduce asthma symptoms by suppressing chemokine-mediated inflammatory responses,” said Fukuda. We look forward to the further development of the molecule to treat the millions of people who suffer from this chronic disease.”
Asthma is a chronic (long-term) lung disease that inflames and narrows the airways. Asthma causes recurring periods of wheezing (a whistling sound when you breathe), chest tightness, shortness of breath, and coughing. The effects are usually temporary, but if the episode is severe, a person may need emergency treatment to restore normal breathing.
Asthma affects people of all ages, but it most often starts during childhood. In the United States, more than 25 million people are known to have asthma, and 60 percent of cases are allergic asthma. About 5 million of these people are children. Despite the availability of treatments, asthma remains poorly controlled among many patients. People with asthma can be of any race, age, or sex, and treatment costs billions of dollars each year.
Join the conversation about asthma research on Facebook and Twitter by using the hash tag #asthma.
About Sanford-Burnham Medical Research Institute
Sanford-Burnham Medical Research Institute is dedicated to discovering the fundamental molecular causes of disease and devising the innovative therapies of tomorrow. Sanford-Burnham takes a collaborative approach to medical research with major programs in cancer, neurodegeneration and stem cells, diabetes, and infectious, inflammatory, and childhood diseases. The Institute is recognized for its National Cancer Institute-designated Cancer Center and expertise in drug discovery technologies. Sanford-Burnham is a nonprofit, independent institute that employs 1,200 scientists and staff in San Diego (La Jolla), Calif., and Orlando (Lake Nona), Fla. For more information, visit us at sanfordburnham.org.
Sanford-Burnham can also be found on Facebook at facebook.com/sanfordburnham and on Twitter @sanfordburnham.
The Asthma and Allergy Foundation of America (AAFA), a not-for-profit organization founded in 1953, is the leading patient organization for people with asthma, allergies, and related conditions. AAFA provides practical information, community based services and support through a national network of chapters, support groups and local community partners. AAFA develops health education, organizes state and national advocacy efforts and funds research to find better treatments and cures. Learn more at www.aafa.org.
Susan Gammon, Ph.D., M.B.A.
Sanford-Burnham Medical Research Institute
cell (858) 610-3808
office (858) 795-5012
Susan Gammon | newswise
High in calories and low in nutrients when adolescents share pictures of food online
07.04.2016 | University of Gothenburg
Brain connectivity reveals hidden motives
04.03.2016 | Universität Zürich
3D printing revolutionized the manufacturing of complex shapes in the last few years. Using additive depositing of materials, where individual dots or lines...
R2D2, a joint project to analyze and development high-TRL processes and technologies for manufacture of flexible organic light-emitting diodes (OLEDs) funded by the German Federal Ministry of Education and Research (BMBF) has been successfully completed.
In contrast to point light sources like LEDs made of inorganic semiconductor crystals, organic light-emitting diodes (OLEDs) are light-emitting surfaces. Their...
High resolution rotational spectroscopy reveals an unprecedented number of conformations of an odorant molecule – a new world record!
In a recent publication in the journal Physical Chemistry Chemical Physics, researchers from the Max Planck Institute for the Structure and Dynamics of Matter...
Strands of cow cartilage substitute for ink in a 3D bioprinting process that may one day create cartilage patches for worn out joints, according to a team of engineers. "Our goal is to create tissue that can be used to replace large amounts of worn out tissue or design patches," said Ibrahim T. Ozbolat, associate professor of engineering science and mechanics. "Those who have osteoarthritis in their joints suffer a lot. We need a new alternative treatment for this."
Cartilage is a good tissue to target for scale-up bioprinting because it is made up of only one cell type and has no blood vessels within the tissue. It is...
Physicists in Innsbruck have realized the first quantum simulation of lattice gauge theories, building a bridge between high-energy theory and atomic physics. In the journal Nature, Rainer Blatt‘s and Peter Zoller’s research teams describe how they simulated the creation of elementary particle pairs out of the vacuum by using a quantum computer.
Elementary particles are the fundamental buildings blocks of matter, and their properties are described by the Standard Model of particle physics. The...
28.06.2016 | Event News
09.06.2016 | Event News
24.05.2016 | Event News
29.06.2016 | Life Sciences
29.06.2016 | Life Sciences
29.06.2016 | Earth Sciences